Page last updated: 2024-09-03
ym 529 and tetradecanoylphorbol acetate
ym 529 has been researched along with tetradecanoylphorbol acetate in 1 studies
Compound Research Comparison
Studies (ym 529) | Trials (ym 529) | Recent Studies (post-2010) (ym 529) | Studies (tetradecanoylphorbol acetate) | Trials (tetradecanoylphorbol acetate) | Recent Studies (post-2010) (tetradecanoylphorbol acetate) |
---|---|---|---|---|---|
140 | 23 | 71 | 31,050 | 61 | 2,217 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Hanai, Y; Harada, A; Kozawa, O; Ohta, T; Takai, S; Tokuda, H | 1 |
Other Studies
1 other study(ies) available for ym 529 and tetradecanoylphorbol acetate
Article | Year |
---|---|
Minodronate suppresses prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts.
Topics: Animals; Cell Line; Dinoprost; Diphosphonates; Imidazoles; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Osteoblasts; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-raf; Tetradecanoylphorbol Acetate; Vascular Endothelial Growth Factor A | 2006 |